CGRP Antagonist Therapy for NEHI Pulmonary Edema
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no specific therapeutic agent for Neuroendocrine Hyperplasia of Infancy (NEHI), a rare childhood lung disease characterized by gas-exchange deficiency, pulmonary edema, and failure to thrive, with the etiology and treatment remaining unclear.
Innovation Solution
Development of a mouse model with a NKX2-1 gene mutation to replicate NEHI symptoms, demonstrating that increased pulmonary neuroendocrine cells (PNECs) secrete calcitonin gene-related peptide (CGRP) leading to pulmonary edema, and treatment with CGRP signaling inhibitors or antagonists to alleviate these symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pulmonary neuroendocrine cells (PNECs) increase in number (PNEC hyperplasia), then gas-exchange efficiency deteriorates, but the cause-effect relationship remains unclear
Solution Approach 1:
The patent extracts the harmful effect by identifying and targeting the specific mechanism through which increased PNECs cause poor gas-exchange. By discovering that PNECs secrete CGRP which disrupts endothelial integrity and causes pulmonary edema, the invention isolates the pathological pathway (CGRP signaling) from the general phenomenon of PNEC hyperplasia, enabling targeted intervention against the harmful effect while potentially preserving normal PNEC functions.
Solution Approach 2:
The patent introduces an intermediary substance (CGRP) that mediates the relationship between PNEC hyperplasia and gas-exchange deficiency. By identifying CGRP as the secreted product linking increased PNEC number to pulmonary edema and poor gas-exchange, the invention provides a mechanistic bridge that explains the cause-effect relationship and enables targeted therapeutic intervention through CGRP signaling inhibition.
2Adaptability or versatility
If there is no specific therapeutic agent for NEHI, then treatment options remain limited to supportive care, but this results in inability to address the underlying pathological mechanism
Solution Approach 1:
The patent applies parameter changes by targeting the CGRP signaling pathway with specific inhibitors or antagonists. By changing the biochemical parameter of CGRP receptor binding or signaling activity, the invention creates a new therapeutic mechanism that directly addresses the underlying pathology of pulmonary edema in NEHI, expanding treatment options beyond supportive care.
Solution Approach 2:
The patent converts the harmful CGRP signaling into a beneficial therapeutic target. By identifying that CGRP secretion by PNECs causes pulmonary edema and poor gas-exchange, the invention transforms this harmful pathway into a specific target for pharmacological intervention, where CGRP inhibitors or antagonists can block the harmful effects and restore normal lung function.
3Reliability
If CGRP signaling is inhibited, then pulmonary edema is reduced and gas-exchange improves, but the mechanism of PNEC hyperplasia persistence remains
Solution Approach 1:
The patent extracts the harmful functional effect (pulmonary edema and poor gas-exchange) from the PNEC hyperplasia by targeting specifically the CGRP signaling pathway. This allows selective intervention against the harmful effects while leaving the PNEC cells themselves intact, addressing the symptomatic manifestation without necessarily requiring elimination of the hyperplastic cells.
Data Source
AI summary
The present disclosure provides a novel animal model of NEHI, and method of preventing and/or treating a pulmonary disease, particularly the lung-based complications in NEHI, such as pulmonary edema, by targeting the PNEC product, such as the CGRP signaling. Also disclosed is the pharmaceutical composition for preventing and/or treating a pulmonary edema and/or other pulmonary disease, particularly, NEHI, comprising one or more CGRP signaling antagonist and/or inhibitor of the present disclosure.